Articles related to HYPERTENSION/BLOOD PRESSURE

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.

The FDA approved baxdrostat (Baxfendy), a selective oral aldosterone synthase inhibitor, as an adjunctive treatment for adults with hypertension uncontrolled on at least two existing antihypertensive agents, including a diuretic.

Daily peppermint oil supplementation was associated with reduced systolic blood pressure and resting heart rate in a small placebo-controlled trial of adults with elevated or stage 1 hypertension.

The critical care nurse has a significant role to play in facilitating timely interventions for intracerebral hemorrhage patients, particularly regarding neurologic status changes and blood pressure control.

In two randomized phase‑3 trials, a single‑pill triple low‑dose antihypertensive combination achieved blood pressure reductions comparable to amlodipine and superior to losartan monotherapy over 8 weeks.

Sdamlo’s FDA approval offers a new oral solution option for delivering amlodipine, addressing administration challenges in patients who cannot tolerate tablets.